Motilal Oswal Maintains Neutral Rating on Alkem Laboratories with Rs 5,890 Target
Motilal Oswal's research report on Alkem Laboratories highlights a marginally better-than-expected revenue and EBITDA performance in the second quarter of FY27, driven by strong growth in the non-US international segment, particularly in LATAM markets. However, subdued trade generics sales in India and lower biotech sales partially offset gains. Earnings were slightly below expectations due to higher depreciation and tax rates. The firm maintains its FY27 and FY28 estimates, valuing Alkem at 27 times forward earnings with a target price of INR 5,890.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (52/100). Lens Score 27/100.
Outlets measured: moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 13 Nov, 05:44 am. Other outlets followed.
- 1